Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma reported promising results from its Phase 2a trials for imdusiran, a potential treatment for chronic hepatitis B, showing potential for a functional cure. Additionally, their oral PD-L1 inhibitor, AB-101, demonstrated safety and receptor occupancy in early trials, positioning the company well for future clinical developments.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
